Apimeds Pharmaceuticals US, Inc. APUS PHARMA
Company Overview
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -85.80% |
| 6 Months: | -82.31% |
| 3 Months: | -82.03% |
| 1 Month: | -45.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)24.85 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 94.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 25 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APUS Apimeds Pharmaceuticals US, Inc. PHARMA | 2.30 | -0.06 | $3.47M | 0.00% | -7.76% | -3.91% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -271.73K | -427.76K | -300.00K | -364.37K | -2.66M | -1.84M | -12.19M |
| Net Income | -296.47K | -449.36K | -332.52K | -402.40K | -2.66M | -1.78M | -35.06M |
| Diluted EPS | -0.04 | -0.06 | -0.04 | -0.05 | -0.26 | -0.14 | -2.26 |
| R&D Expense | - | - | - | - | 651.78K | 619.69K | 901.14K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -747.44K | -1.28M | -11.91M |
| Net Income | -777.69K | -1.39M | -6.00M |
| Diluted EPS | -0.17 | -0.18 | -0.55 |
| R&D Expense | 98.54K | - | 1.63M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 422.08K | 13.06K | 164.18M |
| Total Equity | -713.61K | 31.87K | -1.36M | 153.35M |
| Cash & Equivalents | - | 410.48K | 3.46K | 1.64M |
| Total Liabilities | - | 390.21K | 1.37M | 10.84M |
| Current Liabilities | - | 123.32K | 1.02M | 10.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -627.79K | -733.53K | -8.93M |
| Investing Cash Flow | - | - | -10.06M |
| Financing Cash Flow | 1.03M | 326.50K | 20.62M |
| Capital Expenditure | - | - | -57.33K |
| Free Cash Flow | - | - | -8.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -2,440.3% | 102.3% | -3.9% |
| ROCE % | -250.2% | 126.1% | -7.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Hemenway Trust Company LLC | 18.16% | 274.00K | $484.98K |
| 2 | Vanguard Capital Management LLC | 4.22% | 63.65K | $112.67K |
| 3 | Geode Capital Management, LLC | 2.33% | 35.11K | $62.15K |
| 4 | Vanguard Fiduciary Trust Co | 1.59% | 24.04K | $42.55K |
| 5 | Jane Street Group, LLC | 1.06% | 15.99K | $28.31K |
| 6 | UBS Group AG | 0.78% | 11.82K | $20.92K |
| 7 | Tower Research Capital LLC (TRC) | 0.11% | 1.66K | $2.94K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APUS
APUS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1iWXVfYngteklhOV9aaV80LUVoSDNydHpFMm5NRFF1VEFtak55eVIybUdmVmxjUWRHb2RpdVhKMkR6cmFYWXc?oc=5" target="_blank">APUS</a> <font color="#6f6f6f">Finviz</font>…
Apimeds Pharmaceuticals US to implement 1-for-10 reverse stock split, new CUSIP 03771D201 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdEtjOHBidG9XdnU0LXpyblozdEJYS3RiaUJXOHRLZXdtYThKeVlod1BWaDY0cllWQWxnaEtzdlFJMWxGNXlwbXF0ZGlTUkw0NklaSkZGcTBOZUYzZldzZjFxbUZzN1pmcV9Rb09qTlJUZUYtSjRpamRvSDJOTnp1REdnTWNfVEZKUzhpbH…
Traders are paying attention to the gapping stocks in Wednesday's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPMnVyOFJ2cVZjMEdpbXRzNmpJZGNRN0pSU29vcm5xaEVZbUw3V3poVTF4RnFfZk1PSkRIMGhlb3BGS1ZWb2VoLTVkVzFxU0Z4bWs3ckFjOEVOa2ZfcGtLX015b2NpajF4cnJLSXVvMXdpek1yWElYbkViSm1DMEl1S2hDRkphQ05pSkFTQT…
Apimeds Pharma shares soar on Inscobee settlement - Investing.com
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQUkt4dnV5QzE2cTVhT0dyYl9LYkRZSWVrRzRtZlhQUUF1aTF0YzRyQU9HRDlReS1oZVhJYnJ0U1owQWlVUURPbVNwRnpMVDhpd0VXYVA3eUNhcEZvSnlqZlgwQ1d2b2Z3XzRkckp3TllIVEpPMFhwVkxOdTkzeFZ0N0M2X1dvbGg0OEVRcn…
MindWave Innovations (NYSE American: APUS) Helping Corporations Hold, Manage, and Generate Risk-Aware Yield on Bitcoin Reserves - Barchart.com
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxNVHNKXzU2M01IV0NjLVFibWt5a2dOT1VsRms1czdrbHk1bVlfcGc3YlBFU010NEZ1M0ZNUmljcURpY0JmdEtINS1XMUpXdkxPOEFSSU8zdlI0bC12anI3ZzVuNEpqVnhCbnhQbFJqLXB2NHEwR1V5UkptUWI5OS1URlI1X2pUWGY4WmFBNy…
APUS Forecast — Price Prediction for 2026. Should I Buy APUS? - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE9zY2JNOUl2TmdDcUNGNFhxOVZHeWZLS2ZDRUY3NDNmS0pQMXRGWWJiVktJWmU3bnpqVUlDOEhmbUZFM0NCSTI1eEhDOFMtT0J4OTRwdw?oc=5" target="_blank">APUS Forecast — Price Prediction for 2026. Should I B…
APUS — Frequently Asked Questions
What is the current share price of Apimeds Pharmaceuticals US, Inc. (APUS)?
As of 2026-09-19 21:16 PDT, Apimeds Pharmaceuticals US, Inc. (APUS) trades at $2.30 on NYSE American. Its 52-week range is $2.30 to $38.95.
What is the market capitalisation of APUS?
Apimeds Pharmaceuticals US, Inc. (APUS) has a market capitalisation of $3.47M on NYSE American.
What is the P/E ratio of APUS?
APUS trades at a trailing price-to-earnings (P/E) ratio of -0.06. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.53.
What is the return on equity (ROE) of APUS?
APUS has a return on equity (ROE) of -3.91%. Its return on capital employed (ROCE) is -7.76%.
Is APUS a good stock to buy?
This page provides a data-driven analysis of Apimeds Pharmaceuticals US, Inc. (APUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.